Gradual CBD dose increase for LGS in adults
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests a gradual dose increase of CBD oil (Epidiolex) to see if it helps reduce seizures in adults with Lennox-Gastaut syndrome. It's for people who haven't tried CBD before or haven't used it in at least 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Lennox-Gastaut syndrome (LGS) and have had seizures in the last 6 months.
- You cannot have used CBD oil (Epidiolex or similar) in the last 3 months, or you must be new to this treatment.
- You need to be taking 1 to 3 anti-seizure medications (ASMs) on a stable dose for at least 4 weeks before the study starts.
- You must have had at least 4 major motor seizures (like convulsions or stiffening spells) in the 5 weeks before starting treatment.
- You must have a caregiver who can keep a seizure diary and fill it out at least 80% of the time, with no more than 3 days missed in a row.
- You cannot have used cannabis or CBD products (including oils, edibles, or smoke) in the last 3 months unless you're willing to stop for a month first.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether clemizole helps reduce seizures in people with Lennox-Gastaut syndrome (LGS) and checks safety. If you have LGS and meet the seizure and heart-safety requirements, this could be an option to explore.
This Phase 3 study tests whether carisbamate can reduce drop seizures in people with Lennox-Gastaut syndrome (LGS). It also checks whether the treatment is safe when added to existing seizure medicines.
This trial compares two treatment approaches for children with Lennox-Gastaut syndrome: palliative (comfort-focused) surgery versus adding more anti-seizure medicines. It aims to see which option works better for seizure control and day-to-day well-being.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
This study tests a new CBD patch placed on the skin to see if it can reduce seizures in people with Dravet syndrome or Lennox-Gastaut syndrome. The patch delivers CBD slowly over time, and the goal is to help control seizures that are not well managed by current medications.
This trial tests a new cannabidiol (CBD) liquid medicine for people with focal epilepsy (seizures that start in one part of the brain). It looks at whether the medication can help reduce seizures when added to your current seizure medications.
Hear when a new Lennox-Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.